MedStar Health Georgetown University Hematology and Medical Oncology

Topics

• Cancer Immunotherapy and Biomarkers 237
• Renal cell carcinoma treatment 187
• Lymphoma Diagnosis and Treatment 147
• Estrogen and related hormone effects 144
• BRCA gene mutations in cancer 141
• Bladder and Urothelial Cancer Treatments 134
• Hemophilia Treatment and Research 134
• Lung Cancer Treatments and Mutations 112
• Prostate Cancer Treatment and Research 100
• Breast Cancer Treatment Studies 98
• Monoclonal and Polyclonal Antibodies Research 86
• Melanoma and MAPK Pathways 82

Most cited

1. Enfortumab Vedotin and Pembrolizumab in Untreated Advanced Urothelial Cancer.

   The New England journal of medicine · 2024 · 923 citations · Shilpa Gupta

2. Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: ASCO Guideline Update.

   Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2021 · 1,863 citations · Michael Atkins

3. Individualised neoantigen therapy mRNA-4157 (V940) plus pembrolizumab versus pembrolizumab monotherapy in resected melanoma (KEYNOTE-942): a randomised, phase 2b study.

   Lancet (London, England) · 2024 · 686 citations · Geoffrey Gibney

4. Nivolumab plus ipilimumab versus lenvatinib or sorafenib as first-line treatment for unresectable hepatocellular carcinoma (CheckMate 9DW): an open-label, randomised, phase 3 trial.

   Lancet (London, England) · 2025 · 317 citations · Aiwu He

5. Neoadjuvant-Adjuvant or Adjuvant-Only Pembrolizumab in Advanced Melanoma.

   The New England journal of medicine · 2023 · 739 citations · Geoffrey Gibney, Michael Atkins

6. Prostate Cancer, Version 4.2023, NCCN Clinical Practice Guidelines in Oncology.